BridgeBio Pharma (NASDAQ:BBIO) Issues Earnings Results

Posted by Brenda Bartman on Aug 12th, 2026

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) announced its earnings results on Monday. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20), FiscalAI reports. The business had revenue of $243.68 million during the quarter, compared to analysts’ expectations of $220.91 million. The company’s revenue for the quarter was up 120.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.95) earnings per share.

Here are the key takeaways from BridgeBio Pharma’s conference call:

Attruby net product revenue reached $222.4 million, up $150.9 million year over year and more than $35 million sequentially. Growth was led by treatment-naive, first-line patients, while the company expects additional support from kidney-protection data and real-world evidence.
BridgeBio said Attruby is positioned to benefit from the failed CARDIO-TTRansform combination-therapy study, which it believes reinforces stabilizers as the first-line treatment backbone. Management expects clinical differentiation, including early outcomes and renal benefits, to support further share gains over the next 12–18 months.
All three major pipeline programs advanced into regulatory review: BBP-418 for LGMD2I received priority review with a November 27, 2026 PDUFA date, encaleret for ADH1 received priority review with a May 8, 2027 target date, and infigratinib’s achondroplasia NDA was submitted. The company is building commercial infrastructure for potential launches over the next 12–18 months.
Operating expenses rose to $335.7 million as BridgeBio invested in Attruby and preparations for three launches, though the operating loss improved 20% year over year to $107.1 million. Following a $1 billion preferred-equity financing, management expects operating results to remain roughly stable for several quarters before moving toward breakeven and cash generation in 2027.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO opened at $83.70 on Wednesday. BridgeBio Pharma has a fifty-two week low of $46.81 and a fifty-two week high of $93.42. The firm has a market cap of $16.36 billion, a P/E ratio of -23.45 and a beta of 0.96. The firm has a 50-day simple moving average of $76.47 and a two-hundred day simple moving average of $73.07.

Insider Activity

In other BridgeBio Pharma news, Director Hannah Valantine sold 2,196 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total value of $150,579.72. Following the completion of the sale, the director owned 9,259 shares of the company’s stock, valued at approximately $634,889.63. The trade was a 19.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the completion of the transaction, the chief executive officer owned 535,686 shares in the company, valued at $36,137,377.56. The trade was a 6.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 392,117 shares of company stock worth $29,934,700. 14.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. grew its stake in BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after acquiring an additional 902,648 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in BridgeBio Pharma by 8.9% in the fourth quarter. Mackenzie Financial Corp now owns 54,495 shares of the company’s stock worth $4,105,000 after acquiring an additional 4,448 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of BridgeBio Pharma by 162.4% in the fourth quarter. XTX Topco Ltd now owns 13,169 shares of the company’s stock worth $1,007,000 after buying an additional 8,150 shares during the last quarter. VARCOV Co. purchased a new stake in BridgeBio Pharma during the 4th quarter valued at about $340,000. Finally, Voloridge Investment Management LLC increased its holdings in BridgeBio Pharma by 377.4% in the 4th quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company’s stock worth $48,868,000 after buying an additional 505,051 shares during the period. Institutional investors own 99.85% of the company’s stock.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: Strong Attruby performance drove a revenue beat. Second-quarter revenue reached $243.68 million, exceeding the $220.91 million consensus estimate and rising 120.4% year over year. Attruby U.S. net sales increased 311% year over year, while ex-U.S. Beyonttra royalties rose 62% sequentially. Management reaffirmed guidance for more than $1 billion in 2026 global Attruby and Beyonttra sales. BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
Positive Sentiment: Analysts raised their valuation targets. Piper Sandler increased its target to $115, TD Cowen to $110, Bank of America to $104 and Wells Fargo to $102; Morgan Stanley modestly reduced its target to $97 but maintained an Overweight rating. The firms continue to see substantial upside from current levels.
Positive Sentiment: Pipeline and balance-sheet developments support the growth outlook. BridgeBio expects three product launches by mid-2027, and a $1 billion preferred-equity raise is intended to fund commercial expansion and pipeline investment.
Neutral Sentiment: Upcoming biotech catalysts could add volatility. BridgeBio was identified among biotech companies with important 2026 FDA and late-stage clinical catalysts, which may provide future upside but also carries development and regulatory risk. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Negative Sentiment: The quarterly loss exceeded expectations. BBIO reported a loss of $0.78 per share versus the $0.58 consensus estimate, although the loss improved from $0.95 per share a year earlier. The earnings miss remains a near-term headwind despite the revenue strength.
Negative Sentiment: New employee equity grants create modest dilution. BridgeBio granted restricted stock units representing 66,705 shares to 56 new employees, with vesting beginning in 2027. Reported short interest was zero shares, providing no meaningful short-covering catalyst.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Piper Sandler boosted their target price on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a research report on Tuesday. Raymond James Financial downgraded BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Cantor Fitzgerald restated an “overweight” rating and set a $110.00 target price on shares of BridgeBio Pharma in a research report on Tuesday. Canaccord Genuity Group assumed coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price on the stock. Finally, Mizuho dropped their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a research report on Tuesday, June 16th. Twenty equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average price target of $99.53.

Get Our Latest Report on BridgeBio Pharma

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.